Theralase Technologies (TLT) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024, decreased by 12% year-over-year to CAD 622,984, with declines in Canadian and US markets but a significant increase in international sales; gross margin was 47% due to higher material costs.

• Net loss reduced by 7% year-over-year to CAD 3,337,995, mainly due to lower research and development expenses in the Drug Division.

• Drug division accounted for 84% of the net loss, reflecting continued investment in clinical studies.

• Study II interim data shows 61.9% of evaluable patients achieved complete response, with 43.6% maintaining response at 450 days, and no serious adverse events directly related to the study drug or device.

• Five non-brokered private placements raised over CAD 3.94 million in 2024, supporting ongoing operations and clinical development.

Financial highlights

• Total revenue declined 12% year-over-year, with Canadian revenue down 11%, US revenue down 29%, and international revenue up 1185%.

• Cost of sales was CAD 332,136 (53% of revenue), up from 51% last year, reducing gross margin.

• Selling expenses rose 33% to CAD 257,935, driven by higher sales, salaries, and advertising.

• Administrative expenses fell 11% to CAD 1,294,969, with stock-based compensation down 26%.

• Net R&D expenses dropped 8% to CAD 2,100,699, with drug division R&D down 13% and device division R&D up 297%.

Outlook and guidance

• Estimated cost to complete phase II bladder cancer study is CAD 15–30 million over three years, depending on recruitment and site expansion.

• Plans to secure up to CAD 100 million via a base shelf prospectus, with eligibility requiring CAD 4.5 million in cash flow.

• Additional CAD 10 million to be raised through debt, equity, or government grants to meet eligibility.

• Targeting completion of Study II enrollment in 2025, data lock in mid-2026, and FDA/Health Canada approval by end of 2026, subject to priority review.

• Phase I-B studies for brain and lung cancer estimated at CAD 5 million each, to be funded via the base shelf prospectus.